Cargando…

Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection

BACKGROUND: Interest in phage therapy has grown over the past decade due to the rapid emergence of antibiotic resistance in bacterial pathogens. However, the use of bacteriophages for therapeutic purposes has raised concerns over the potential for immune response, rapid toxin release by the lytic ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Vivek Daniel, Sundarrajan, Sudarson, Rajagopalan, Sanjeev Saravanan, Hariharan, Sukumar, Kempashanaiah, Nanjundappa, Padmanabhan, Sriram, Sriram, Bharathi, Ramachandran, Janakiraman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224134/
https://www.ncbi.nlm.nih.gov/pubmed/21880144
http://dx.doi.org/10.1186/1471-2180-11-195
_version_ 1782217347362193408
author Paul, Vivek Daniel
Sundarrajan, Sudarson
Rajagopalan, Sanjeev Saravanan
Hariharan, Sukumar
Kempashanaiah, Nanjundappa
Padmanabhan, Sriram
Sriram, Bharathi
Ramachandran, Janakiraman
author_facet Paul, Vivek Daniel
Sundarrajan, Sudarson
Rajagopalan, Sanjeev Saravanan
Hariharan, Sukumar
Kempashanaiah, Nanjundappa
Padmanabhan, Sriram
Sriram, Bharathi
Ramachandran, Janakiraman
author_sort Paul, Vivek Daniel
collection PubMed
description BACKGROUND: Interest in phage therapy has grown over the past decade due to the rapid emergence of antibiotic resistance in bacterial pathogens. However, the use of bacteriophages for therapeutic purposes has raised concerns over the potential for immune response, rapid toxin release by the lytic action of phages, and difficulty in dose determination in clinical situations. A phage that kills the target cell but is incapable of host cell lysis would alleviate these concerns without compromising efficacy. RESULTS: We developed a recombinant lysis-deficient Staphylococcus aureus phage P954, in which the endolysin gene was rendered nonfunctional by insertional inactivation. P954, a temperate phage, was lysogenized in S. aureus strain RN4220. The native endolysin gene on the prophage was replaced with an endolysin gene disrupted by the chloramphenicol acetyl transferase (cat) gene through homologous recombination using a plasmid construct. Lysogens carrying the recombinant phage were detected by growth in presence of chloramphenicol. Induction of the recombinant prophage did not result in host cell lysis, and the phage progeny were released by cell lysis with glass beads. The recombinant phage retained the endolysin-deficient genotype and formed plaques only when endolysin was supplemented. The host range of the recombinant phage was the same as that of the parent phage. To test the in vivo efficacy of the recombinant endolysin-deficient phage, immunocompromised mice were challenged with pathogenic S. aureus at a dose that results in 80% mortality (LD(80)). Treatment with the endolysin-deficient phage rescued mice from the fatal S. aureus infection. CONCLUSIONS: A recombinant endolysin-deficient staphylococcal phage has been developed that is lethal to methicillin-resistant S. aureus without causing bacterial cell lysis. The phage was able to multiply in lytic mode utilizing a heterologous endolysin expressed from a plasmid in the propagation host. The recombinant phage effectively rescued mice from fatal S. aureus infection. To our knowledge this is the first report of a lysis-deficient staphylococcal phage.
format Online
Article
Text
id pubmed-3224134
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32241342011-11-26 Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection Paul, Vivek Daniel Sundarrajan, Sudarson Rajagopalan, Sanjeev Saravanan Hariharan, Sukumar Kempashanaiah, Nanjundappa Padmanabhan, Sriram Sriram, Bharathi Ramachandran, Janakiraman BMC Microbiol Research Article BACKGROUND: Interest in phage therapy has grown over the past decade due to the rapid emergence of antibiotic resistance in bacterial pathogens. However, the use of bacteriophages for therapeutic purposes has raised concerns over the potential for immune response, rapid toxin release by the lytic action of phages, and difficulty in dose determination in clinical situations. A phage that kills the target cell but is incapable of host cell lysis would alleviate these concerns without compromising efficacy. RESULTS: We developed a recombinant lysis-deficient Staphylococcus aureus phage P954, in which the endolysin gene was rendered nonfunctional by insertional inactivation. P954, a temperate phage, was lysogenized in S. aureus strain RN4220. The native endolysin gene on the prophage was replaced with an endolysin gene disrupted by the chloramphenicol acetyl transferase (cat) gene through homologous recombination using a plasmid construct. Lysogens carrying the recombinant phage were detected by growth in presence of chloramphenicol. Induction of the recombinant prophage did not result in host cell lysis, and the phage progeny were released by cell lysis with glass beads. The recombinant phage retained the endolysin-deficient genotype and formed plaques only when endolysin was supplemented. The host range of the recombinant phage was the same as that of the parent phage. To test the in vivo efficacy of the recombinant endolysin-deficient phage, immunocompromised mice were challenged with pathogenic S. aureus at a dose that results in 80% mortality (LD(80)). Treatment with the endolysin-deficient phage rescued mice from the fatal S. aureus infection. CONCLUSIONS: A recombinant endolysin-deficient staphylococcal phage has been developed that is lethal to methicillin-resistant S. aureus without causing bacterial cell lysis. The phage was able to multiply in lytic mode utilizing a heterologous endolysin expressed from a plasmid in the propagation host. The recombinant phage effectively rescued mice from fatal S. aureus infection. To our knowledge this is the first report of a lysis-deficient staphylococcal phage. BioMed Central 2011-08-31 /pmc/articles/PMC3224134/ /pubmed/21880144 http://dx.doi.org/10.1186/1471-2180-11-195 Text en Copyright ©2011 Paul et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Paul, Vivek Daniel
Sundarrajan, Sudarson
Rajagopalan, Sanjeev Saravanan
Hariharan, Sukumar
Kempashanaiah, Nanjundappa
Padmanabhan, Sriram
Sriram, Bharathi
Ramachandran, Janakiraman
Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection
title Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection
title_full Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection
title_fullStr Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection
title_full_unstemmed Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection
title_short Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection
title_sort lysis-deficient phages as novel therapeutic agents for controlling bacterial infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224134/
https://www.ncbi.nlm.nih.gov/pubmed/21880144
http://dx.doi.org/10.1186/1471-2180-11-195
work_keys_str_mv AT paulvivekdaniel lysisdeficientphagesasnoveltherapeuticagentsforcontrollingbacterialinfection
AT sundarrajansudarson lysisdeficientphagesasnoveltherapeuticagentsforcontrollingbacterialinfection
AT rajagopalansanjeevsaravanan lysisdeficientphagesasnoveltherapeuticagentsforcontrollingbacterialinfection
AT hariharansukumar lysisdeficientphagesasnoveltherapeuticagentsforcontrollingbacterialinfection
AT kempashanaiahnanjundappa lysisdeficientphagesasnoveltherapeuticagentsforcontrollingbacterialinfection
AT padmanabhansriram lysisdeficientphagesasnoveltherapeuticagentsforcontrollingbacterialinfection
AT srirambharathi lysisdeficientphagesasnoveltherapeuticagentsforcontrollingbacterialinfection
AT ramachandranjanakiraman lysisdeficientphagesasnoveltherapeuticagentsforcontrollingbacterialinfection